Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.
Amolyt Pharma has raised $138.6M in total funding. The most recent round was Series C. The last funding was announced in January 2023.
Amolyt Pharma's investors include Bpifrance, Intermediate Capital Group, Andera Partners, OrbiMed, Sofinnova Partners.
Amolyt Pharma is headquartered in Écully, France.
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.
Amolyt Pharma is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amolyt Pharma — Funding & Investors." VCBacked, January 6, 2023, https://www.vcbacked.co/company/amolyt-pharma. Accessed August 15, 2026.
VCBacked. (2023). Amolyt Pharma — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/amolyt-pharma
{{cite web |title=Amolyt Pharma — Funding & Investors |url=https://www.vcbacked.co/company/amolyt-pharma |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated